Add office photos
Engaged Employer
Cipla
4.1
based on 6.5k Reviews
Proud winner of ABECA 2024 - AmbitionBox Employee Choice Awards
Company Overview
Associated Companies
Company Locations
Working at Cipla
Company Summary
Cipla is a leading Global Pharmaceutical Company that ensures access to quality & affordable medicines through various products across various therapeutic categories.
Overall Rating
4.1/5
based on 6.5k reviews
16% above
industry average
Highly rated for
Skill Development, Salary & Benefits, Work-Life Balance
Work Policy
Work from office
72% employees reported
Alternate Saturday off
38% employees reported
Flexible timing
56% employees reported
Within city
39% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
599 employees reported
Health insurance
572 employees reported
Office cab/shuttle
274 employees reported
Professional degree assistance
196 employees reported
View all benefits
About Cipla
Founded in1935 (89 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersMumbai, Maharashtra, India
Office Locations
Websitecipla.com
Primary Industry
Other Industries
At Cipla, we constantly work towards ensuring access to high quality and affordable medicines to support patients in need. Which is why, we have been trusted by health care professionals and patients across geographies for the last 8 decades. Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.
Report error
Cipla Subsidiaries
Cipla Health
4.1
• 288 reviews
Report error
AmbitionBox Best Places to Work in India Awards
Best of the best, rated by employees
Cipla won India’s Largest Employee Choice Awards in Large Companies Category.
#2 Top Rated Pharma Company
Share
Cipla Ratings
based on 6.5k reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
3.3k
4
1.8k
3
789
2
278
1
427
Category Ratings
4.0
Skill Development
4.0
Salary & Benefits
3.9
Work-Life Balance
3.9
Company Culture
3.8
Work Satisfaction
3.7
Job Security
3.6
Promotions/Appraisal
Cipla is rated 4.1 out of 5 stars on AmbitionBox, based on 6.5k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Cipla
based on 6.2k reviews
4.1
Rated by 626 Women
Rated 3.9 for Skill Development and 3.9 for Work-Life Balance
4.1
Rated by 5.5k Men
Rated 4.0 for Skill Development and 4.0 for Salary & Benefits
Work Policy at Cipla
based on 545 reviews in last 6 months
Work from office
72%
Hybrid
22%
Permanent work from home
6%
Cipla Reviews
Top mentions in Cipla Reviews
+ 5 more
Compare Cipla with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.1/5 based on 6.5k reviews | 4.2/5 based on 5.8k reviews | 4.1/5 based on 5.5k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Skill development Salary & Benefits Work-Life balance | Skill development Company culture Work-Life balance | Salary & Benefits Job Security Skill development | Skill development Work-Life balance Salary & Benefits |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 72% employees reported | Work from office 85% employees reported | Work from office 87% employees reported | - |
Rating by Women Employees | 4.1 Good rated by 626 women | 4.0 Good rated by 337 women | 4.1 Good rated by 404 women | - no rating available |
Rating by Men Employees | 4.1 Good rated by 5.5k men | 4.2 Good rated by 5.1k men | 4.1 Good rated by 4.8k men | - no rating available |
Job Security | 3.7 Good | 3.7 Good | 3.9 Good | 4.0 Good |
View more
Cipla Salaries
4.0
rated by 6.5k employees for salariesDeputy Manager
(1.1k salaries)
Unlock
₹5.3 L/yr - ₹18 L/yr
Area Business Manager
(614 salaries)
Unlock
₹4.4 L/yr - ₹12 L/yr
Therapy Manager
(533 salaries)
Unlock
₹2.4 L/yr - ₹7.1 L/yr
Territory Manager
(371 salaries)
Unlock
₹1.6 L/yr - ₹7.3 L/yr
Medical Representative
(370 salaries)
Unlock
₹1.9 L/yr - ₹7 L/yr
Regional Business Manager
(303 salaries)
Unlock
₹7 L/yr - ₹17.5 L/yr
Production Officer
(251 salaries)
Unlock
₹1.1 L/yr - ₹8.1 L/yr
Scientific Business Manager
(214 salaries)
Unlock
₹4.5 L/yr - ₹10.5 L/yr
Trainee
(198 salaries)
Unlock
₹1.2 L/yr - ₹4 L/yr
Area Sales Manager
(196 salaries)
Unlock
₹4.5 L/yr - ₹11 L/yr
Cipla Interview Questions
Interview questions by designation
Top interview questions and answers
Get interview-ready with top interview questions
Interview Process at Cipla
based on 114 interviews in last 1 year
Interview Experience
4.2
Good
Difficulty level
Easy
19%
Moderate
70%
Hard
11%
People are getting interviews through
based on 324 Cipla interviews
Job Portal
25%
Company Website
18%
Walkin
18%
Referral
15%
*24% candidates got the interview through other sources
High confidence
Cipla Jobs
Cipla News
View all
Six Stocks In News At Noon: Cipla To Shriram Finance — Top Gainers And Losers
- Cipla, ITC, and Adani Ports were the top gainers in the market at noon.
- Cipla's stock rose by 0.91% following an upgrade by Kotak Securities.
- ITC gained 0.63% after announcing the demerger date for its hotel business.
- Adani Ports saw a gain of 0.58% after achieving a major milestone at its Mundra Port.
- Shriram Finance's stock dropped by 3.92% despite strong demand for its financial services.
Bloomberg Quint | 17 Dec, 2024
Cipla Becomes Top Gainer In Nifty 50 As Kotak Institutional Upgrades To Buy
- Cipla Ltd.'s share price rose to become the top gainer on the NSE Nifty 50 index after Kotak Securities upgraded the stock rating to 'buy'. The brokerage expects recovery in the domestic market and healthy growth in the South African market.
- Kotak Securities reduced the target price but still implied a 19.09% upside from the current closing price. It estimates 9.5% reported earnings per share and compound annual growth rate over FY24 and FY27.
- Cipla stock was impacted by various factors, but Kotak Securities believes most concerns are already factored in the stock price, leading to the upgrade in stock rating.
- Cipla share price rose 2.39% to Rs 1,483.00 apiece and has been rising for three consecutive sessions. Analysts maintain a 'buy' rating on the stock with an average 12-month consensus price target implying a 9.4% upside.
Bloomberg Quint | 17 Dec, 2024
Cipla’s ‘inhaled insulin’ from US’ MannKind Corp adds a ‘layer of convenience’ for those with diabetes
- Cipla has received approval to distribute and market Afrezza, an inhaled insulin, in India.
- Afrezza provides more convenience for individuals with diabetes who are wary of injections.
- The inhaled insulin is not recommended for those with asthma, COPD, and serious lung-related concerns.
- Cipla plans to make Afrezza available by the end of the financial year, pending pricing finalization.
HinduBusinessLine | 12 Dec, 2024
Cipla to bring in inhaled insulin Afreeza from US’ MannKind Corporation
- Cipla has received approval from CDSCO to distribute and market Afrezza, an inhaled insulin powder.
- Afrezza improves glycemic control in adult patients with diabetes mellitus.
- It is the first and only non-injectable insulin for both type 1 and type 2 diabetes mellitus.
- Cipla will partner with MannKind Corporation to supply and distribute Afrezza in India.
HinduBusinessLine | 12 Dec, 2024
Buy, Sell Or Hold: BEL, L&T, Britannia, Voltas, SpiceJet — Ask Profit
- Aditya Arora and Lancelot Dcunha provided expert advice on buying, selling, and holding shares of BEL, L&T, Britannia, Voltas, SpiceJet, Tata Motors, and more on NDTV Profit's Ask Profit show.
- Aditya Arora suggests selling Heritage Foods and holding SpiceJet, while Lancelot Dcunha advises waiting before accumulating Cipla shares.
- Aditya Arora recommends buying Britannia, holding BEL, Voltas, MOIL, and NALCO, and selling Tata Motors on rise.
- Lancelot Dcunha suggests holding L&T and Tata Motors, and adds that Voltas is attempting a breakout.
Bloomberg Quint | 11 Dec, 2024
Cipla to bring in inhaled insulin Afreeza from US’ MannKind Corporation
- The Central Drugs Standard Control Organisation (CDSCO) has given Cipla the approval to distribute and market Afrezza inhalation powder in India.
- Afrezza, developed by MannKind Corporation, is a non-injectable insulin for patients with type 1 and type 2 diabetes mellitus.
- The inhalable insulin starts working in as early as 12 minutes and helps reduce the rapid increase in sugar levels with meals.
- Cipla will distribute Afrezza in India, offering a convenient solution for people uncomfortable with needles.
HinduBusinessLine | 11 Dec, 2024
Cipla To Sun Pharma: Here Are HSBC's Top Pharma Stock Picks
- HSBC has identified its top picks in the Indian pharmaceutical sector, maintaining a buy rating on Cipla Ltd., Sun Pharmaceutical Industries Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., and Aurobindo Pharma Ltd.
- HSBC believes the loss of gRevlimid sales from January 2026 is already priced into the valuations for Cipla and Sun Pharma.
- Stable generic pricing and the execution of key product launches in the US are expected to drive performance in 2025.
- Increasing focus on complex generics and GLP-1 drugs, such as liraglutide, is also seen as crucial for sustaining growth in the US market.
Bloomberg Quint | 11 Dec, 2024
Share Market Highlights: Sensex, Nifty dip; RBI’s CRR cut eases liquidity worries
- The GDP growth projection for FY25 has been slashed to 6.6% from the earlier 7.2% indicating the effects of high food inflation.
- The RBI has continued to maintain a neutral stance to support growth and indicate a low-rate regime in sight.
- Tata Motors and Bajaj Auto were among the top gainers while Cipla and Adani Ports were among the top losers.
- UltraTech Cement slipped 0.73% on the NSE, while Piramal Pharma’s stock fell 2.55% on the NSE.
- Nifty index remains in buy on dips mode as it traded higher for the past 5 trading sessions.
- According to Jefferies, the current price action suggests that the index may move further upwards.
- Mishtann Foods' stock plummeted 19.97% on the BSE after SEBI ordered the company to recover nearly Rs. 100 crore.
- RBI’s Monetary Policy meeting was held today.
- As per the report, liquidity management crucial, CRR cut a possibility.
- Indian IPO market soars to $17.3 bn so far in 2024 and is nearing record highs.
HinduBusinessLine | 6 Dec, 2024
Market midday update: Sensex and Nifty tread cautiously as sectoral trends emerge
- Sectoral trends in the market reveal a mixed landscape, with auto and consumer-focused stocks performing well.
- Bajaj Auto, Axis Bank, Maruti Suzuki, ITC, and Titan are the key gainers driving the market's overall performance.
- Healthcare and IT stocks faced pressure, with HDFC Life, Cipla, IndusInd Bank, Infosys, and Wipro experiencing declines.
- The Nifty Next 50 and Nifty Midcap Select indices showed positive gains, while the Nifty Bank index slightly declined.
HinduBusinessLine | 6 Dec, 2024
Markets surge ahead, tech and consumer stocks lead midday rally
- Technology and consumer discretionary stocks drove the midday rally in the markets.
- Stocks like Titan, Infosys, Adani Enterprises, TCS, and Bharti Airtel led the gainers.
- Bajaj Auto, SBI Life, NTPC, HDFC Life, and Cipla faced selling pressure.
- Sectoral indices showed mixed performance, with the Nifty Bank and Nifty Financial Services indices gaining, while the Nifty Next 50 and Nifty Midcap Select indices had marginal changes.
HinduBusinessLine | 5 Dec, 2024
Powered by
Compare Cipla with
Biocon Limited
3.9
Zydus Lifesciences
4.2
Glenmark Pharmaceuticals
4.0
Torrent Pharmaceuticals
3.9
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.8
Alkem Laboratories
3.9
Dr. Reddy's
4.1
Viatris
4.2
Abbott
4.2
Alembic Pharmaceuticals
4.0
Ipca Laboratories
4.0
Ajanta Pharma
4.0
Akums Drugs & Pharmaceuticals Limited
4.3
GlaxoSmithKline Pharmaceuticals
4.1
Cadila Pharmaceuticals
3.5
Pfizer
4.0
Wockhardt
3.9
Piramal Group
3.9
Sanofi
4.3
Contribute & help others!
You can choose to be anonymous
Companies Similar to Cipla
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.1
• 5.5k reviews
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 5.8k reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.8k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.2
• 5.8k reviews
Glenmark Pharmaceuticals
Pharma
4.0
• 2.7k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.4k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.6k reviews
DIVI'S Laboratories
Pharma
3.8
• 1.3k reviews
Alkem Laboratories
Healthcare / Pharma, Biotechnology, Pharma
3.9
• 2.8k reviews
Dr. Reddy's
Clinical Research, Pharma
4.1
• 6.5k reviews
Viatris
Manufacturing, Pharma
4.2
• 3k reviews
Cipla FAQs
When was Cipla founded?
Where is the Cipla headquarters located?
How many employees does Cipla have in India?
Does Cipla have good work-life balance?
Is Cipla good for career growth?
What are the pros of working in Cipla?
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
70 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
